Xeltis’ Post

TNO is excited joining Digital Medicine Society (DiMe)'s new project: "Building the Business Case for Digital Endpoints”, will establish effective measures to monitor and benchmark the value of digital endpoints, aiming to help organisations build a compelling case for continued investment in digital strategies. This team will develop resources that: ➡️ Establish shared industry benchmarks for assessing the ROI of digital endpoints in drug development and medical device innovation ➡️ Support organisations in building the business case for digital endpoints ➡️ Help organisations make informed decisions and sustain investment in integrating digital endpoints TNO’s digital health innovations help transform clinical research by integrating digital biomarkers and endpoints into trials. These measures enhance precision, patient engagement, and accelerate new therapies > https://tno.social/pvw 🔗 Learn more about the project > https://lnkd.in/ej6YnfSi Annika van Rosmalen Willem van den Brink

For investors and others interested in startups in the precision medicine space check out the demo day happening next week: https://lnkd.in/edgnpC8g The P4 accelerator programme is about facilitating the scale and adoption of precision medicine startups by providing access to unparalleled expertise in genomic profiling, drug targeting, disease marker discovery, diagnostics/companion diagnostics, clinical trials design, engineering, artificial intelligence, regulatory compliance and health data. See you there Lotus Qi

Thrilled to be speaking at the 23rd Annual Bio-IT World Conference & Expo in Boston this April 15-17, 2024 alongside Vasu Nadella, CEO and co-founder of Vital Biosciences. We'll be diving into the transformative journey of healthcare from traditional centralized laboratories to innovative decentralized home-based diagnostics. Our session aims to uncover the profound implications of this shift, emphasizing patient empowerment and the revolutionary approaches to care delivery in an era brimming with technological breakthroughs. This year's Bio-IT World Conference & Expo promises an enriching experience, with over 300 distinguished speakers across 10 focused tracks, exploring themes at the heart of precision medicine such as #GenerativeAI, #DigitalTwins, #HumanVirtualModels, and #AI for #DrugDiscovery, among others. It's an unparalleled opportunity to share best practices, engage in interactive discussions, and network with a global community of experts in #lifesciences, #pharmaceuticals, #healthcare, and #technology. If you're planning to be there or in the area, let me know! I'd love to connect. #BioITExpo #PrecisionMedicine #DecentralizedDiagnostics #PatientEmpowerment #HealthcareInnovation #BiomedicalResearch #DrugDevelopment Bio-IT World

🎉 Exciting News! Attention, PE-Investors! 🎉 After some incredibly exciting weeks, I am proud to announce a strategic cooperation with Transgenion. Transgenion, a spin-off of the Medical University of Vienna, is a unique research and development company, founded by Prof. Dr. Rolf Ziesche. By integrating medical, biological, and analytical excellence, Transgenion develops innovative tools for precision medicine against the most challenging chronic inflammatory diseases (CIDs) of advanced age, Chronic Obstructive Pulmonary Disease (COPD) and Pulmonary Fibrosis. Whether it's refining internal processes, enhancing external communication strategies, or optimizing SOPs, my team and I are committed to providing Transgenion with comprehensive support. We look forward to playing an important role in their journey towards groundbreaking advancements in precision medicine. Unique Investment Opportunity: After three decades of extensive clinical and molecular research, backed by the EU Research & Innovation funding program „Horizon Europe“ with € 19.5 Mio. and in collaboration with esteemed institutions globally, Transgenion is now approaching another round of financing. This funding will ensure the successful implementation of the CORE Programs. Starting with the CORE Programs, Transgenion is realizing the first useful diagnosis and causal treatment for CID. The completion of Phase 2 marks the equivalent pharmaceutical development value at € 450 Mio. The future of medicine is individual. The term coined for this is Personalized Medicine. A completely new world is just around the corner and you have a unique opportunity to be a part of it. The company's ongoing digitization effort is in progress. I'll be giving regular updates on its progress in the coming weeks. For more detailed information and the pitch deck, feel free to get in touch! #medicine #VC #privateEquity

🚀 AI-Powered Healthcare Partnership! Novo Nordisk partners with Valo Health to harness the power of Artificial Intelligence in discovering treatments for cardiometabolic diseases like heart attack, stroke, and diabetes. 💡 By leveraging Valo's Opal Computational Platform, real-world patient data, and AI-enabled small molecule discovery, this collaboration aims to revolutionize drug development and improve our understanding of target biology. 💰 Valo Health receives $60 million upfront and the potential for milestone payments totaling up to $2.7 billion, marking a significant commitment to advancing healthcare through AI. 🩺 As the healthcare industry continues to embrace cutting-edge technology, collaborations like this bring us closer to groundbreaking treatments and solutions for critical diseases. #HealthcareInnovation #AIinHealthcare #CardiometabolicDiseases #MedicalAdvancements

The Scottish Life Science Summit served as a platform for biotech, medtech, and healthtech companies to exchange insights and discuss the industry's future in Northeast Scotland. Notable participants included EpitogenX, Microplate Dx Limited, TauRx, NovaBiotics Ltd, and Elasmogen Ltd. The UK is a global force in life sciences. Remarkably, it hosts 14% of global clinical trials. Emphasising the 4 P's— prioritising patients, places, partnerships, and people— is key to sector growth. Life science aims to enhance longevity, happiness, and well-being. What role do you play in shaping the future of life sciences? #lifescience #clinicalresearch #innovation

Check out our latest blog post for a deep dive into the cutting-edge advancements shaping the future of medicine and beyond. Read more at: https://lnkd.in/gW7mjRuK #BioFuture #Innovation #BlogPost

Exosomes are here to stay! 💪🏼 Since launching BENEV Exosomes into the market in 2017, there has been an explosion of Exosome Business in the U.S. 👇🏼Check out some of these stats: 2018 Exosome Market Share — $550k 2023 Exosome Market Share — $12M 💰Projected 2024 Exosome Market Share — $23M NOW is the time to do your research and review the different Exosome brands out there! If you swipe, you will see some compelling evidence that showcases the intensive research, clinical papers and studies that back up the science behind the @benevexosomes! No one else has an equivalent amount of clinical data and patents to support their product. PLUS, it has been used by over 1 Million U.S. patients. Want to schedule a meeting? 📲 DM us today and we would love to walk you through the power of BENEV Exosomes! #exosomes #benevexosomes #exosomecomplex #exosomeapplications #exosomesoothinggelmask #monarchaestheticservices

Hallo from Munich!! 👋 🇩🇪 The #REPO4EU consortium has arrived in the Bavarian city to celebrate the 4th #GeneralAssembly, hosted at Technische Universität München (Technical University of Munich)... there's a lot to catch up on before we officially kick off #RExPO24 tomorrow afternoon 🤩 If you're wondering what we've been up to, these are some of the crucial topics we've been discussing 👇 💊 Current status of the project, challenges and goals for next period (we're close to our 2nd anniversary already!) 💊 Crucial elements we need to implement for our #DrugRepurposing platform, with a big focus on #PatientNetworks and #RareDiseases 💊 A close first look at what our online platform will look like - lots of exciting developments happening in this area! 💊 Upcoming in-silico trials and potential new connections with further European #ClinicalData banks 💊 How to increase the impact of our research through ScienceOpen's Drug Repurposing Central (https://lnkd.in/ef4cCjaN) 💊 Location options for #RExPO25 next year!! Collaboration and knowledge exchange is at the heart of our project, and we're so fortunate to count on such a diverse pool of experts! As always, a big thank you to all the wonderful #REPO4EU partners for their continuous contributions and hard work towards shaping up the #FutureOfMedicine 🌟 Maastricht University, tp21 GmbH, Universität Wien, GeneSurge, STALICLA, Universität Hamburg, Technical University of Munich, Invicol GmbH, Sciomics, Universidad Politécnica de Madrid, DiHeSys - Digital Health Systems GmbH, H.M. Pharma Consultancy, Ipsis Pactis, AUSTRALO, Karolinska University Hospital, Brigham and Women's Hospital, Universitätsklinikum Bonn, Research Institute (RI), Arega Medical, Egnosis, 3D-PharmXchange, Radboudumc, Maastricht UMC+, ScienceOpen, BioLizard, Universidade do Porto, Machine2Learn, a Silo AI Company and University of Zurich.

Exosomes are here to stay! 💪🏼 Since launching BENEV Exosomes into the market in 2017, there has been an explosion of Exosome Business in the U.S. 👇🏼Check out some of these stats: 2018 Exosome Market Share — $550k 2023 Exosome Market Share — $12M 💰Projected 2024 Exosome Market Share — $23M NOW is the time to do your research and review the different Exosome brands out there! If you swipe, you will see some compelling evidence that showcases the intensive research, clinical papers and studies that back up the science behind the @benevexosomes! No one else has an equivalent amount of clinical data and patents to support their product. PLUS, it has been used by over 1 Million U.S. patients. Want to schedule a meeting? 📲 DM us today and we would love to walk you through the power of BENEV Exosomes! #exosomes #benevexosomes #exosomecomplex #exosomeapplications #exosomesoothinggelmask #monarchaestheticservices